Use of Cystatin C to Assess Kidney Function
Previously, the Mayo Clinic renal laboratory used a nephelometric assay for cystatin C. When samples were recently run using both platforms, we found that there was a 23% bias, with the newer PETIA assay being higher than the previous nepholmetric assay or PENIA.
Comparison To Current Assay Reveals Bias
Jump to section:
- A Case
- What do the kidneys do?
- Why Measure Renal Function?
- How Is Chronic Kidney Disease (CKD) Defined?
- Stages of Chronic Kidney Disease
- Laboratory Assessment of Kidney Function: What Can We Measure?
- Creatinine as a Marker of GFR
- Creatinine as a Marker of GFR: It Works But...
- How Can We Turn the Serum Creatinine Into a Better Estimate of GFR?
- Revised eGFR Equation (ID-MS version)
- eGFR Equation Works, But it's Not Perfect
- What About Cystatin C?
- Mayo Renal Laboratory Cystatin C By Particle Enhanced Turbidometric Immunoassay (PETIA)
- Comparison To Current Nephelometric Assay (PENIA) Reveals 23% Bias
- Cystatin C PENIA Assay Shift (19%)
- Cystatin C eGFR Using Published Equation* Performs Well3
- Cystatin C Equations Categorize Patients Slightly Better Than MDRD eGFR
- Cystatin C Reference Range
- PETIA Cystatin C Reference Range
- Cystatin C: Useful To Confirm Those At Risk Of CKD Progression And Its Complications (REGARDS)4
- Cystatin C: CKD Progression and Complications (MESA and CHS)5
- Cystatin C in the Acute Hospitalized Setting6
- Back to Our Patient
- Potential Interventions